# Abbott Laboratories vs Novo Nordisk: stocks compared

URL: https://funkfolio.com/compare/abt-vs-nvo

> Abbott Laboratories ($181.4B, P/E 39.1) and Novo Nordisk ($179.4B, P/E 10.3) compared: size, valuation, margins, debt, cash and price change.

---

## Abbott Laboratories vs Novo Nordisk

Abbott Laboratories (ABT), health care, and Novo Nordisk (NVO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Abbott Laboratories and Novo Nordisk are valued at about the same: $181.4B and $179.4B. Abbott Laboratories trades at 39.1 times earnings and Novo Nordisk at 10.3; operating margins in their latest fiscal years were 18.2% and 41.3%. Over the past year Abbott Laboratories's share price has moved -17.3% and Novo Nordisk's -12.5%.

### Key facts

- **Abbott Laboratories market value:** $181.4B
- **Novo Nordisk market value:** $179.4B
- **Abbott Laboratories P/E:** 39.1
- **Novo Nordisk P/E:** 10.3
- **Abbott Laboratories revenue:** $44.3B FY to 2025-12-31
- **Novo Nordisk revenue:** $45.9B FY to 2025-12-31
- **Superinvestors holding both:** 1

Market values as of 18 Nov 2026, 06:44 UTC.

Abbott Laboratories vs Novo Nordisk: every measure side by side

| Measure | Abbott Laboratories | Novo Nordisk |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Denmark |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $181.4B higher | $179.4B lower |
| Revenue | $44.3B lower | $45.9B higher |
| Earnings | $6.5B lower | $15.2B higher |
| Employees | 122,000 higher | 68,794 lower |
| Total assets | $86.7B higher | $80.6B lower |
| Valuation |  |  |
| P/E | 39.1 higher | 10.3 lower |
| P/S | 4.1 higher | 3.9 lower |
| P/B | 3.6 | — |
| Dividend yield | 2.35% | — |
| Profitability |  |  |
| Operating margin | 18.2% lower | 41.3% higher |
| Balance sheet |  |  |
| Net assets | $52.1B higher | $28.8B lower |
| Total liabilities | $33.9B lower | $51.8B higher |
| Total debt | $12.9B lower | $19.4B higher |
| Cash on hand | $8.5B higher | $3.9B lower |
| Price change |  |  |
| Today | -2.55% lower | -2.16% higher |
| 1 year | -17.3% lower | -12.5% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Abbott Laboratories 80.5, Novo Nordisk 84.0.

- Abbott Laboratories (ABT)
- Novo Nordisk (NVO)

Abbott Laboratories and Novo Nordisk share prices over one year, rebased to 100: Abbott Laboratories ends at 80.5, Novo Nordisk at 84.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ABT | NVO |
| --- | --- | --- |
| Nov 28, 2025 | 99.1 | 101.8 |
| Dec 31, 2025 | 96.4 | 105.0 |
| Jan 30, 2026 | 84.1 | 122.6 |
| Feb 27, 2026 | 89.5 | 77.3 |
| Mar 31, 2026 | 79.0 | 75.8 |
| Apr 30, 2026 | 69.8 | 87.1 |
| May 29, 2026 | 65.8 | 94.1 |
| Jun 30, 2026 | 69.8 | 98.9 |
| Jul 31, 2026 | 81.3 | 97.2 |
| Aug 31, 2026 | 84.9 | 93.5 |
| Sep 30, 2026 | 76.0 | 78.2 |
| Oct 30, 2026 | 81.7 | 82.5 |
| Nov 17, 2026 | 80.5 | 84.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (1)

- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4% / 0.4%

#### Abbott Laboratories only (14)

- [Mason Hawkins](https://funkfolio.com/gurus/mason-hawkins) 4.0%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 2.4%
- [Diamond Hill team](https://funkfolio.com/gurus/diamond-hill) 2.2%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.9%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.7%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.5%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.4%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.3%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 0.1%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1%

#### Novo Nordisk only (7)

- [Tom Gayner](https://funkfolio.com/gurus/tom-gayner) 0.8%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) 0.7%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.6%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 0.4%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.2%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Abbott Laboratories / Novo Nordisk). [Who owns ABT](https://funkfolio.com/stock/ABT/superinvestors) · [Who owns NVO](https://funkfolio.com/stock/NVO/superinvestors)

### More on Abbott Laboratories

- [Abbott Laboratories (ABT) stock page](https://funkfolio.com/stock/ABT)
- [Abbott Laboratories market cap](https://funkfolio.com/stock/ABT/market-cap)
- [Abbott Laboratories revenue](https://funkfolio.com/stock/ABT/revenue)
- [Abbott Laboratories P/E ratio](https://funkfolio.com/stock/ABT/pe-ratio)
- [Abbott Laboratories operating margin](https://funkfolio.com/stock/ABT/operating-margin)
- [Abbott Laboratories total debt](https://funkfolio.com/stock/ABT/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novo Nordisk

- [Novo Nordisk (NVO) stock page](https://funkfolio.com/stock/NVO)
- [Novo Nordisk market cap](https://funkfolio.com/stock/NVO/market-cap)
- [Novo Nordisk revenue](https://funkfolio.com/stock/NVO/revenue)
- [Novo Nordisk P/E ratio](https://funkfolio.com/stock/NVO/pe-ratio)
- [Novo Nordisk operating margin](https://funkfolio.com/stock/NVO/operating-margin)
- [Novo Nordisk total debt](https://funkfolio.com/stock/NVO/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Abbott Laboratories against its closest peers

- [Abbott Laboratories vs Gilead Sciences](https://funkfolio.com/compare/abt-vs-gild)
- [Abbott Laboratories vs Pfizer](https://funkfolio.com/compare/abt-vs-pfe)
- [Abbott Laboratories vs Danaher](https://funkfolio.com/compare/abt-vs-dhr)

#### Novo Nordisk against its closest peers

- [Novo Nordisk vs Pfizer](https://funkfolio.com/compare/nvo-vs-pfe)
- [Novo Nordisk vs Danaher](https://funkfolio.com/compare/dhr-vs-nvo)
- [Novo Nordisk vs Intuitive Surgical](https://funkfolio.com/compare/isrg-vs-nvo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Abbott Laboratories or Novo Nordisk?**

By market value, Abbott Laboratories is the larger: $181.4B against $179.4B for Novo Nordisk. By revenue in its latest fiscal year, Novo Nordisk is the larger: $45.9B against $44.3B for Abbott Laboratories.

**Which has the higher P/E ratio?**

Abbott Laboratories: 39.1, against 10.3 for Novo Nordisk. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Novo Nordisk: 41.3%, against 18.2% for Abbott Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Novo Nordisk: $19.4B, against $12.9B for Abbott Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Abbott Laboratories and Novo Nordisk?**

In their latest 13F filings, John Overdeck and David Siegel (founders) holds both.

### Cite this page

Funkfolio, “Abbott Laboratories vs Novo Nordisk”, data as of 18 November 2026. https://funkfolio.com/compare/abt-vs-nvo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
